Solventum Corporation (NYSE:SOLV) Short Interest Update
by Doug Wharley · The Cerbat GemSolventum Corporation (NYSE:SOLV – Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 5,383,477 shares, a growth of 35.7% from the March 15th total of 3,967,922 shares. Based on an average trading volume of 1,534,187 shares, the days-to-cover ratio is currently 3.5 days. Currently, 3.1% of the shares of the stock are short sold.
Insiders Place Their Bets
In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.24% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in SOLV. Assetmark Inc. boosted its holdings in shares of Solventum by 21.4% during the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after purchasing an additional 128 shares during the last quarter. Hilltop National Bank grew its holdings in Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the period. Allworth Financial LP grew its holdings in Solventum by 2.8% in the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after buying an additional 129 shares during the period. CIBC Private Wealth Group LLC increased its stake in shares of Solventum by 0.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after acquiring an additional 134 shares during the last quarter. Finally, BOKF NA increased its stake in shares of Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after acquiring an additional 141 shares during the last quarter.
Analyst Ratings Changes
Several research firms have recently commented on SOLV. Wells Fargo & Company upgraded shares of Solventum to a “hold” rating in a research report on Wednesday, March 18th. Mizuho set a $100.00 price objective on Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Piper Sandler set a $92.00 target price on Solventum in a report on Friday. Finally, Stifel Nicolaus raised their price target on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Solventum has an average rating of “Hold” and a consensus price target of $90.09.
View Our Latest Stock Analysis on SOLV
Solventum Trading Up 3.5%
Shares of Solventum stock traded up $2.41 during mid-day trading on Friday, hitting $71.29. 134,676 shares of the stock were exchanged, compared to its average volume of 1,218,397. The stock has a market capitalization of $12.36 billion, a price-to-earnings ratio of 8.03, a price-to-earnings-growth ratio of 1.13 and a beta of 0.71. Solventum has a twelve month low of $62.38 and a twelve month high of $88.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The company has a 50-day simple moving average of $69.59 and a 200 day simple moving average of $74.76.
Solventum (NYSE:SOLV – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The company’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.41 earnings per share. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Research analysts forecast that Solventum will post 6.58 EPS for the current year.
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.